Compare iShares MSCI France ETF (EWQ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Johnson & Johnson — how do they compare? iShares MSCI France ETF trades at $41.51 (market cap $330.91M), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 1867.8× iShares MSCI France ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and Johnson & Johnson for 129 Days on average.
| EWQ | JNJ | |
|---|---|---|
Market Cap | $330.91M | $618.09B |
Volume | 556,654 | 6,050,983 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $278.43 |
52-Week Low | $41.32 | $186.00 |
Typical Hold Time | 55 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.52 with a slight 0.44% daily gain, though technical indicators show a bearish bias with moving averages signaling strong selling pressure. The stock faces mixed sentiment with oscillators suggesting potential oversold conditions while European market uncertainties create headwinds. Recent news highlights ECB rate hikes and energy-driven inflation concerns affecting European equities.
The stock's outlook remains cautious with technical weakness offset by potential oversold bounce opportunities. Key risks include European economic sentiment deterioration and persistent inflation pressures, while the absence of fundamental data requires careful monitoring of upcoming financial disclosures for valuation clarity.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
